Search | Pharmaceuticals

11 - 20 of about 169 Documents

Advancing Innovation May Advance Latin America's Economies, Part 1/3

Innovations in pharma need framework conditions that adapt to the constantly changing environment and the ever new challenges in terms of innovation and market access.

https://pharma.bayer.com/advancing-innovation-may-advance-latin-americas-economies-part-13

Advancing Innovation May Advance Latin America’s Economies, Part 2/3

Local parameters shape the framework conditions for innovations in pharma in Latin America.

https://pharma.bayer.com/advancing-innovation-may-advance-latin-americas-economies-part-23

Advancing Innovation May Advance Latin America’s Economies, Part 3/3

In this 3-part series we’ve explored fundamental, detailed drivers and components for innovation in Latin America.

https://pharma.bayer.com/advancing-innovation-may-advance-latin-americas-economies-part-33

Germany Joins the Fight Against NTDs

Neglected tropical diseases (NTDs) affect over one billion people worldwide. Many of those affected live in poverty with poor sanitary conditions and in close contact with infectious vectors.

https://pharma.bayer.com/germany-additional-force-change-fight-against-ntds

Value Considerations in nmCRPC

In 1853, the first case of prostate cancer was documented and described as “a very rare disease”. Now, more than 150 years later, prostate cancer has become one of the most common diseases among men.

https://pharma.bayer.com/value-considerations-non-metastatic-stage-prostate-cancer

Chinese people on scooter crossing an intersection

Institutional Reform Towards Healthy China 2030

Against the backdrop of Healthy China 2030, the Chinese government has gone through the most significant restructuring in years, consisting of personnel changes and a departmental shake-up.

https://pharma.bayer.com/healthy-china-2030-institutional-reshuffle-improve-healthcare-quality-and-prices

Healthy China 2030: China’s Healthcare Journey

The World Bank’s joint report with the Chinese government found that, without health care reform, health spending would increase to USD 2.5 trillion in 2035, up from USD 543.5 billion in 2014.

https://pharma.bayer.com/healthy-china-2030-chinas-healthcare-journey

A Look at the Chinese Market

China is one of the largest pharmaceutical markets in the world - and a field of tension between unique to disruptive medical innovations and generic products.

https://pharma.bayer.com/look-chinese-market

Healthy China 2030: Pooled Procurement Price Pressure

As part of Healthy China 2030, the Chinese government has opted to ramp up pressure on reimbursement negotiations and procurement processes.

https://pharma.bayer.com/healthy-china-2030-pressure-prices-under-pooled-procurement

Healthy China 2030: Strategy to Tackle Cancer

Cancer is on the rise in China. In 2014, the country saw 2.3 million deaths from the disease and 3.8 million new cases, accounting for more than one fifth of premature deaths and more than a quarter of new cancer cases worldwide.

https://pharma.bayer.com/healthy-china-2030-spotlight-chinas-strategy-tackle-cancer